
- /
- Supported exchanges
- / US
- / ITOS.NASDAQ
Iteos Therapeutics Inc (ITOS NASDAQ) stock market data APIs
Iteos Therapeutics Inc Financial Data Overview
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cellular cytotoxicity activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonist program; EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to reverse immunosuppression and restore T cell proliferation in the tumor microenvironment; and EOS-215, a monoclonal antibody which antagonizes triggering receptor expressed on triggering receptor expressed on myeloid cells 2. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Iteos Therapeutics Inc data using free add-ons & libraries
Get Iteos Therapeutics Inc Fundamental Data
Iteos Therapeutics Inc Fundamental data includes:
- Net Revenue: 35 000 K
- EBITDA: -148 648 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-08
- EPS/Forecast: -0.9035
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Iteos Therapeutics Inc News

iTeos Therapeutics Announces Its Intention to Wind Down Operations
- Board of Directors intends to cease operations - Company to focus efforts on selecting best path to deliver near-term value to shareholders - Exploring potential asset sales including EOS-984, EOS...


Cancer drugmaker iTeos to shut down
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: Cancer drugmaker iTeos Therapeutics said...

GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug
GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston Pharmaceuticals to acquire the latter’s lead pipeline drug, efimosfermin alfa. Efimos...

iTeos verkündet Topline-Zwischenergebnisse der GALAXIES Lung-201-Studie für die First-Line-Behandlung mit Belrestotug und Dostarlimab von Krebspatienten, die von einem nicht-kleinzelligen Lungenkarzinom mit hoher PD-L1-Expression betroffen sind
– GALAXIES Lung-201 erfüllte nicht die festgelegten Kriterien für klinisch bedeutsame Verbesserungen beim progressionsfreien Überleben – Ausgehend von der Gesamtheit der Daten haben sich iTeos...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.